Can a new targeted pill boost chemotherapy against a tough lung cancer?
NCT ID NCT06514027
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This trial is testing whether an experimental drug called BEBT-109, taken as a pill, can safely and effectively work alongside standard chemotherapy to treat a specific type of non-small cell lung cancer that has a particular genetic change (EGFR exon 20 insertion). The study involves adults with advanced or recurrent disease who have not yet received treatment. Participants will receive BEBT-109 plus chemotherapy (pemetrexed with either carboplatin or cisplatin) in 21-day cycles, and researchers will monitor how well the cancer responds and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BEBT-109 (an experimental targeted drug) combined with chemotherapy (pemetrexed and carboplatin or cisplatin)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with a specific type of lung cancer that currently has limited targeted therapy choices.
- What could go wrong
- This is an early-phase, small study (30 participants), so results may not be conclusive. The drug combination may cause side effects or may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Real-World data confirm T-DXd's promise in HER2-Mutant lung cancer?
- Can an Immune-Boosting antibody extend life in advanced lung cancer?
- Can focused radiation boost Immunotherapy's power against advanced cancer?
- Can a Dual-Drug combo shrink lung tumors before surgery?
- Can a Cell-Derived vaccine hold lung cancer at bay?
- Can a new immunotherapy combo outsmart advanced lung cancer?